Skip to end of metadata
Go to start of metadata

You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 26 Next »

Summary

The Cancer Genome Atlas (TCGA) Renal Phenotype Research Group is part of the Cancer Imaging Program TCGA Radiology Initiative focused on analyzing images from the TCGA-kidney renal clear cell carcinoma (KIRC) collection. Multiple modalities of images which correlate to the KIRC data in the TCGA Data Portal are being gathered for submission to The Cancer Image Archive (TCIA).

For kidney cancer, TCGA will create a reference genome, against which new patients will be compared, for both clear cell and papillary cancer types. According to the NIH, the initial objectives of TCGA for kidney cancer are:

  • Identify unique patterns of genomic changes that divide clear cell and papillary carcinoma tumors into subgroups.
  • Identify genomic differences that distinguish tumors across gender, race, or ethnicity.
  • Determine if specific patterns of genomic changes are connected to tumor recurrence after therapy.

Research and Publications

Data Source

Status

TCGA Data Portal Publication Guidelines

No restrictions; all data available without limitations.

TCIA Data Usage Policies and Restrictions

No restrictions; all data available without limitations.

Please contact us at cancerimagingarchive@mail.nih.gov if you have any questions about these policies.

TCGA-KIRC Marker Paper and Image Source Sites (ISS)

Imaging Source Site (ISS) Groups will be populated and governed by participants from institutions that have provided imaging data to the archive for a given cancer type. Modeled after TCGA analysis groups, ISS groups are given the opportunity to publish a marker paper for a given cancer type per TCGA Publication Guidelines. This opportunity will generate increased participation in building these multi-institutional data sets as they become an open community resource. Current TCGA-KIRC source sites include:

  • Memorial Sloan-Kettering Cancer Center
  • University of Pittsburgh / UPMC
  • Mayo
  • NCI Urologic Oncology Branch
  • UNC

Please contact Dr. Oguz Akin (akino@mskcc.org) if you have scientific questions for TCGA-KIRC ISS or are interested in collaborating with their group.

References

The following links contain publications from the main TCGA project as well as their posted publication guidelines:

2nd Annual TCGA Symposium

  • Adverse Outcomes in Clear Cell Renal Cell Carcinoma With Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2
    • Ari Hakimi, MD, Memorial Sloan-Kettering Cancer Center
    • Video | Slides
  • TCGA Clear Cell Renal Cell Carcinoma Project
    • Chad J. Creighton, PhD, Baylor College of Medicine
    • Video | Slides
  • No labels